Back to search
FDAFDA · Food and drugs·Recall number D-0636-2020

Mirtazapine Tablets, USP, 15 mg, 500-count tablets, Rx only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810 NDC 13107-031-05

Published December 18, 2019 · Recall initiated: November 20, 2019

Summary

FDA records drug Class I recall D-0636-2020, published December 18, 2019 and initiated November 20, 2019. Recalling firm: AuroMedics Pharma LLC; Status: Terminated; Reported quantity: N/A; Lot: Lot #: 03119002A3, Exp 3/2022. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Label Error on Declared Strength; cases labelled Mirtazapine 15mg tablets, 500-count bottles, contain 500-count bottles of Mirtazapine 15mg tablets labelled as Mirtazapine 7.5 mg tablets.

What to do

Voluntary: Firm initiated · Letter

Get an email if MIRTAZAPINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
MIRTAZAPINE
Manufacturer
AuroMedics Pharma LLC
Distributor
Nationwide
Lot
Lot #: 03119002A3, Exp 3/2022
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Mirtazapine Tablets, USP, 15 mg, 500-count tablets, Rx only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810 NDC 13107-031-05 recalled?

Yes. FDA published recall D-0636-2020 on December 18, 2019. Reported hazard: Labeling: Label Error on Declared Strength; cases labelled Mirtazapine 15mg tablets, 500-count bottles, contain 500-count bottles of Mirtazapine 15mg tablets labelled as Mirtazapine 7.5 mg tablets.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: MIRTAZAPINE.